Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celcuity Inc.CELC · Entity 3991 | Director · Chief Science Officer | August 14, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celcuity Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,271,000 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 20,000 · Balance 1,271,000 F1: 25% of the total number of restricted stock units vests on the first day of the month following each of the first, second, third and fourth anniversaries of the grant date. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,000 |
Reported balance
After 2026-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-14 · Grant · Acquired 10,000 · Balance 10,000 F2: Each performance stock unit represents a contingent right to receive one share of Celcuity Inc. (the "Company") common stock. The performance stock units vest upon the Company's common stock achieving certain specified trailing average per share price thresholds. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total number of restricted stock units vests on the first day of the month following each of the first, second, third and fourth anniversaries of the grant date.
F2: Each performance stock unit represents a contingent right to receive one share of Celcuity Inc. (the "Company") common stock. The performance stock units vest upon the Company's common stock achieving certain specified trailing average per share price thresholds.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 18, 2026 20:19 UTC | Celcuity Inc. CELC · Entity 3991 | GrantPerformance Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001716041-26-000004 · form4-08182026_080858.xml · derivative · entry 2 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of Celcuity Inc. (the "Company") common stock. The performance stock units vest upon the Company's common stock achieving certain specified trailing average per share price thresholds. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of Celcuity Inc. (the "Company") common stock. The performance stock units vest upon the Company's common stock achieving certain specified trailing average per share price thresholds. F2 · derivative.expiration_date: Each performance stock unit represents a contingent right to receive one share of Celcuity Inc. (the "Company") common stock. The performance stock units vest upon the Company's common stock achieving certain specified trailing average per share price thresholds. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 20:19 UTC | Celcuity Inc. CELC · Entity 3991 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001716041-26-000004 · form4-08182026_080858.xml · nonDerivative · entry 1 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,271,000 F1 · shares: 25% of the total number of restricted stock units vests on the first day of the month following each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:52 UTC | Celcuity Inc. CELC · Entity 3991 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0001716041-26-000002 · form4-06042026_080657.xml · derivative · entry 2 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,250 Underlying: Common Stock · 1,000 shares Expires 2033-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:52 UTC | Celcuity Inc. CELC · Entity 3991 | Exercise / conversionCommon Stock | 1,000 | $9.89 | $9,890.00 |
DisclosureSEC source: 0001716041-26-000002 · form4-06042026_080657.xml · nonDerivative · entry 1 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,251,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:30 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $51.57 | $0.00 |
DisclosureSEC source: 0001415889-25-022447 · form4-08202025_040804.xml · derivative · entry 1 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-08-18 F1 · derivative.exercise_date: 25,000 shares vest on 8/18/2026; the remaining 75,000 shares vest 1/36th per month thereafter. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:02 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 10,962 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001415889-25-004378 · form4-02182025_090255.xml · derivative · entry 1 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,962 Underlying: Common Stock · 10,962 shares Expires 2035-02-13 F1 · derivative.exercise_date: These shares vest in full on February 21, 2025. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:25 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001062993-24-015559 · form4.xml · derivative · entry 18 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-08-20 F11 · derivative.exercise_date: 25,000 shares vest on 8/20/25; the remaining 75,000 shares vest 1/36th per month thereafter. Read SEC document |
| August 20, 2024 Filed Aug 26, 2024 21:41 UTC Amendment | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001062993-24-015671 · form4a.xml · derivative · entry 1 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-08-20 F1 · derivative.exercise_date: 25,000 shares vest on 8/20/25; the remaining 75,000 shares vest 1/36th per month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:24 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 7,765 | $0.00 Strike: $15.03 | $0.00 |
DisclosureSEC source: 0001062993-24-003326 · form4.xml · derivative · entry 17 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,765 Underlying: Common Stock · 7,765 shares Expires 2034-02-13 F11 · derivative.exercise_date: These shares vest in equal amounts on the first day of each month over twelve (12) months, beginning March 1, 2024. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 20:42 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0001062993-23-017209 · form4.xml · derivative · entry 16 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-08-25 F11 · derivative.exercise_date: 31,250 shares vest on 8/25/24; the remaining 93,750 shares vest 1/36th per month thereafter. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 20:42 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 21,250 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0001062993-23-017209 · form4.xml · derivative · entry 15 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 21,250 shares Expires 2033-08-25 F10 · derivative.exercise_date: These shares vest in equal amounts on the last day of each month over seventeen (17) months, beginning August 31, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:24 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 9,156 | $0.00 Strike: $11.55 | $0.00 |
DisclosureSEC source: 0001062993-23-004232 · form4.xml · derivative · entry 14 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,156 Underlying: Common Stock · 9,156 shares Expires 2033-02-16 F11 · derivative.exercise_date: These shares vest in equal amounts over twelve (12) months, beginning February 16, 2023. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (Right to Buy) · Derivative | 38,412 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 22 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,412 Underlying: Common Stock · 38,412 shares Expires 2032-05-17 F12 · derivative.exercise_date: These shares vest in equal amounts over fourteen (14) months, beginning June 1, 2022. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 1,877 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 21 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,877 Underlying: Common Stock · 1,877 shares Expires 2031-10-27 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F11 · derivative.exercise_date: 469 shares vest on 10/27/22; the remaining 1,408 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | Disposition to issuerStock Option (right to buy) · Derivative | 1,877 | Not disclosed Strike: $17.19 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 20 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,877 shares Expires 2031-10-27 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F11 · derivative.exercise_date: 469 shares vest on 10/27/22; the remaining 1,408 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 19 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-11 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F10 · derivative.exercise_date: 5,000 shares vest on 8/11/22; the remaining 15,000 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $20.04 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 18 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2031-08-11 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F10 · derivative.exercise_date: 5,000 shares vest on 8/11/22; the remaining 15,000 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 6,754 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 17 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,754 Underlying: Common Stock · 6,754 shares Expires 2031-04-12 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F9 · derivative.exercise_date: 1,689 shares vest on 4/12/22; the remaining 5,065 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | Disposition to issuerStock Option (right to buy) · Derivative | 6,754 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 16 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,754 shares Expires 2031-04-12 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F9 · derivative.exercise_date: 1,689 shares vest on 4/12/22; the remaining 5,065 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 2,973 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 15 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,973 Underlying: Common Stock · 2,973 shares Expires 2031-03-18 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F8 · derivative.exercise_date: 743 shares vest on 3/18/22; the remaining 2,230 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | Disposition to issuerStock Option (right to buy) · Derivative | 2,973 | Not disclosed Strike: $15.92 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 14 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,973 shares Expires 2031-03-18 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F8 · derivative.exercise_date: 743 shares vest on 3/18/22; the remaining 2,230 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 3,215 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 13 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,215 Underlying: Common Stock · 3,215 shares Expires 2031-02-02 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F7 · derivative.exercise_date: 803 shares vest on 2/2/22; the remaining 2,412 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | Disposition to issuerStock Option (right to buy) · Derivative | 3,215 | Not disclosed Strike: $14.84 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 12 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,215 shares Expires 2031-02-02 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F7 · derivative.exercise_date: 803 shares vest on 2/2/22; the remaining 2,412 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 2,771 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 11 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock · 2,771 shares Expires 2030-12-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F6 · derivative.exercise_date: 692 shares vest on 12/29/21; the remaining 2,079 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | Disposition to issuerStock Option (right to buy) · Derivative | 2,771 | Not disclosed Strike: $10.35 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 10 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,771 shares Expires 2030-12-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F6 · derivative.exercise_date: 692 shares vest on 12/29/21; the remaining 2,079 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 8 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-08-12 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F4 · derivative.exercise_date: 12,500 shares vest on 8/12/20; the remaining 37,500 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $19.72 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 7 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-08-12 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F4 · derivative.exercise_date: 12,500 shares vest on 8/12/20; the remaining 37,500 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 1,834 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 6 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,834 Underlying: Common Stock · 1,834 shares Expires 2019-10-17 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F3 · derivative.exercise_date: 458 shares vest on 10/17/19; the remaining 1,376 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | Disposition to issuerStock Option (right to buy) · Derivative | 1,834 | Not disclosed Strike: $25.77 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 5 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,834 shares Expires 2028-10-17 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F3 · derivative.exercise_date: 458 shares vest on 10/17/19; the remaining 1,376 shares vest 1/36th per month thereafter. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 4,110 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 4 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,110 Underlying: Common Stock · 4,110 shares Expires 2027-09-19 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 17, 2022 Filed May 20, 2022 00:37 UTC | Celcuity Inc. CELC · Entity 3991 | Disposition to issuerStock Option (right to buy) · Derivative | 4,110 | Not disclosed Strike: $9.50 | Not disclosed |
DisclosureSEC source: 0001437749-22-013127 · rdgdoc.xml · derivative · entry 3 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,110 shares Expires 2027-09-19 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| October 27, 2021 Filed Oct 29, 2021 20:46 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 1,877 | $0.00 Strike: $17.19 | $0.00 |
DisclosureSEC source: 0000914190-21-000382 · edgar.xml · derivative · entry 12 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,877 Underlying: Common Stock · 1,877 shares Expires 2031-10-27 F10 · derivative.exercise_date: 469 shares vest on 10/27/22; the remaining 1,408 shares vest 1/36th per month thereafter. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:02 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $20.04 | $0.00 |
DisclosureSEC source: 0000914190-21-000259 · edgar.xml · derivative · entry 11 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-11 F9 · derivative.exercise_date: 5,000 shares vest on 8/11/22; the remaining 15,000 shares vest 1/36th per month thereafter. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 21:47 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 6,754 | $0.00 Strike: $27.94 | $0.00 |
DisclosureSEC source: 0000914190-21-000118 · edgar.xml · derivative · entry 10 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,754 Underlying: Common Stock · 6,754 shares Expires 2031-04-12 F8 · derivative.exercise_date: 1,689 shares vest on 4/12/22; the remaining 5,065 shares vest 1/36th per month thereafter. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:24 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 2,973 | $0.00 Strike: $15.92 | $0.00 |
DisclosureSEC source: 0000914190-21-000087 · edgar.xml · derivative · entry 9 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,973 Underlying: Common Stock · 2,973 shares Expires 2031-03-18 F7 · derivative.exercise_date: 743 shares vest on 3/18/22; the remaining 2,230 shares vest 1/36th per month thereafter. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:12 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 3,215 | $0.00 Strike: $14.84 | $0.00 |
DisclosureSEC source: 0000914190-21-000030 · edgar.xml · derivative · entry 8 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,215 Underlying: Common Stock · 3,215 shares Expires 2031-02-02 F6 · derivative.exercise_date: 803 shares vest on 2/2/22; the remaining 2,412 shares vest 1/36th per month thereafter. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 22:38 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 2,771 | $0.00 Strike: $10.35 | $0.00 |
DisclosureSEC source: 0000914190-20-000468 · edgar.xml · derivative · entry 7 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock · 2,771 shares Expires 2030-12-28 F5 · derivative.exercise_date: 692 shares vest on 12/29/21; the remaining 2,079 shares vest 1/36th per month thereafter. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:20 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000914190-20-000297 · edgar.xml · derivative · entry 6 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-08-12 F4 · derivative.exercise_date: 5,000 shares vest on 8/12/21; the remaining 15,000 shares vest 1/36th per month thereafter. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:10 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $19.72 | $0.00 |
DisclosureSEC source: 0000914190-19-000300 · edgar.xml · derivative · entry 5 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-08-12 F3 · derivative.exercise_date: 12,500 shares vest on 8/12/20; the remaining 37,500 shares vest 1/36th per month thereafter. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 21:20 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 1,834 | $0.00 Strike: $25.77 | $0.00 |
DisclosureSEC source: 0001144204-18-054600 · tv505120_4.xml · derivative · entry 4 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,834 Underlying: Common Stock · 1,834 shares Expires 2028-10-17 F2 · derivative.exercise_date: 458 shares vest on 10/17/19; the remaining 1,376 shares vest 1/36th per month thereafter. Read SEC document |
| September 19, 2017 Filed Oct 16, 2017 20:26 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 4,110 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0000914190-17-000312 · edgar.xml · derivative · entry 3 Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,110 Underlying: Common Stock · 4,110 shares Expires 2027-09-19 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.